Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections
Summary
Purpose of the study: * To assess efficacy of Anaferon for children liquid dosage form in the treatment of acute upper respiratory tract infections. * To assess safety of Anaferon for children liquid dosage form in the treatment of acute upper respiratory tract infections.
Timeline
- Start
- 2015-01-22
- Primary completion
- 2015-04-29
- Completion
- 2015-04-29
Outcome
Met primary endpoint
registry MEAN Anaferon for Children: 87.7 (Standard Deviation 31.5) hours NCT03162458 ↗
registry analysis (superiority test); Anaferon for Children vs Placebo; p = 0.007; Wilcoxon (Mann-Whitney) NCT03162458 ↗
registry MEAN Anaferon for Children: 25.6 (Standard Deviation 17.2) AUC score*day NCT03162458 ↗
registry analysis (superiority test); Anaferon for Children vs Placebo; p = 0.0004; Wilcoxon (Mann-Whitney) NCT03162458 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anaferon | Unknown | 10 unknown | — |